Windhover Pharmaceutical Strategic Alliances

Sep. 21, 2009-Sep. 23, 2009
Millennium Broadway Hotel
New York, NY
www.windhover.com/psa

Description:

Ben Bonifant, Vice President and head of the Business Development Practice at Campbell Alliance, will participate in a panel discussion at this event titled "What is Reimbursable Innovation?."

Abstract:

What is Reimbursable Innovation?

Ultimately the answer to this question affects both your deal making and financing, as investors recognize the need to gauge an asset’s value not just in potential partners’ eyes, but increasingly in the eyes of cost-conscious payers as well.  We’ll hear from Andrew Dillon, CEO of the UK’s Institute for Clinical Excellence on how the watchdog places a monetary value on it in its cost-effectiveness calculations, as well as top Big Pharma and Big Biotech dealmakers and investors on how the changes are affecting their decision-making.  Discussions include:
  • Comparing and contrasting with the fast-evolving US situation, emphasizing the actual and potential impact of the Comparative Effectiveness legislation on the industry
  • Business development: how, and in what way, these questions (and the uncertainties around them) are affecting deal making and portfolio prioritization decisions today
  • VCs: how the reimbursement landscape impacts new company creation
  • Has reimbursement uncertainty forced a company to rule out specific product types or therapeutic areas? 

Moderator:

Melanie Senior
Bureau Chief, Europe
Elsevier Business Intelligence

Panelists:

Ben Bonifant
Vice President and Head of the Business Development Practice
Campbell
Alliance

Andrew Dillon
CEO

National Institute for Health and Clinical Excellence (NICE)


Ian Spatz
Managing Director
EBI Advisors


David Mott
General Partner
New Enterprise Associates
Former MedImmune CEO


Peter Wirth
Executive Vice President, Legal and Corporate Development
Genzyme Corporation

View Entire Event Calendar

Don't Miss